Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Multi-Dose Study of SGN-30 (anti-CD30 monoclonal antibody) in Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma
2004-000607-17Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Aug 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iratumumab in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), sponsored by Seagen Inc. Primary endpoint: Objective tumor response in Hodgkin's disease. Started Aug 2004; status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2004-000607-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000607-17.